Video

Dr. Antonarakis on the Utility of Sipuleucel-T Plus Radium-223 in Nonmetastatic CRPC

Emmanuel S. Antonarakis, MBBCh, discusses the utility of sipuleucel-T plus radium-223 in nonmetastatic castration-resistant prostate cancer.

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses the utility of sipuleucel-T (Provenge) plus radium-223 (Xofigo) in nonmetastatic castration-resistant prostate cancer (CRPC).

Radium-223 is a bone-targeting radiopharmaceutical that emits an alpha particle, says Antonarakis.

As such, it is not likely to have efficacy in patients with nonmetastatic CRPC or rising prostate-specific antigen who do not have bone metastases, explains Antonarakis.

Sipuleucel-T is currently approved in metastatic CRPC. It is unknown whether sipuleucel-T and radium-223 can prevent bone metastases in patients with nonmetastatic CRPC. However, without a target, a drug like radium-223 may not be effective, concludes Antonarakis.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS